Growth factor expression in ophthalmic pterygia and normal conjunctiva

被引:40
作者
Detorakis, Efstathios T. [1 ]
Zaravinos, Apostolos [2 ]
Spandidos, Demetrios A. [2 ]
机构
[1] Univ Hosp Hereklion, Dept Ophthalmol, Iraklion 71110, Crete, Greece
[2] Univ Crete, Sch Med, Virol Lab, Iraklion, Crete, Greece
关键词
pterygium; growth factors; qRT-PCR; HUMAN NASAL POLYPOSIS; EPITHELIAL-CELLS; RADIATION; THERAPIES; CANCER; IGF1; FGF2; EGF;
D O I
10.3892/ijmm_00000371
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The expression of growth factors in ophthalmic pterygium and phenotypically normal conjunctiva was examined and correlated with the clinical findings. Fifteen specimens of ophthalmic pterygia and 8 specimens of phenotypically normal conjunctiva were examined Total RNA was extracted from all specimens and mRNA levels for transforming growth factor (TGFB1). vascular endothelial growth factor (VEGFA). basic fibroblast growth factot(FGF2). epidermal growth factor (EGF) and insulin-like growth factor (IFG1) were measured using real-time reverse-transcription PCR (qRT-PCR). Differences in the expression of these factors between pterygium and conjunctival specimens were examined. as well its correlations between RNA levels and clinical parameters. mRNA levels for VEGFA and FGF2 were significantly higher in pterygium, compared with conjunctival specimens. whereas the respective differences for other factors examined were statistically not significant The mRNA levels for VEGFA and FGF2 were also significantly higher in recruitment compared with primary pterygium Correlations between the mRNA levels and other clinical parameters were statistically not significant for the growth Factors examined. The higher levels of FGF-2 or VEGFA mRNA in pterygium imply that these Factors may be involved In the pathogenesis or clinical behavior of the pterygium, including postoperative recurrence VEGFA expression may have potential for use in the selective treatment of pterygium with anti-VEGFA agents
引用
收藏
页码:513 / 516
页数:4
相关论文
共 22 条
[1]   Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium [J].
Bahar, Irit ;
Kaiserman, Igor ;
McAllum, Penny ;
Rootman, David ;
Slomovic, Allan .
CURRENT EYE RESEARCH, 2008, 33 (01) :23-28
[2]   Vascular endothelial growth factor causally contributes to the angiogenic response upon ultraviolet B irradiation in vitro [J].
Blaudschun, R ;
Sunderkötter, C ;
Brenneisen, P ;
Hinrichs, R ;
Peters, T ;
Schneider, L ;
Razi-Wolf, Z ;
Hunzelmann, N ;
Scharffetter-Kochanek, K .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (04) :581-587
[3]   PTERYGIUM AS AN EARLY INDICATOR OF ULTRAVIOLET INSOLATION - A HYPOTHESIS [J].
CORONEO, MT .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1993, 77 (11) :734-739
[4]   Vascular complications of selected cancer therapies [J].
Daher, Iyad N. ;
Yeh, Edward T. H. .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2008, 5 (12) :797-805
[5]   Evaluation of loss of heterozygosity and microsatellite instability in human pterygium: clinical correlations [J].
Detorakis, ET ;
Sourvinos, G ;
Tsamparlakis, J ;
Spandidos, DA .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1998, 82 (11) :1324-1328
[6]  
Detorakis ET, 2000, INT J MOL MED, V6, P35
[7]   UVB-elicited induction of MMP-1 expression in human ocular surface epithelial cells is mediated through the ERKI/2 MAPK-dependent pathway [J].
Di Girolamo, N ;
Coroneo, MT ;
Wakefield, D .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (11) :4705-4714
[8]   Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases [J].
Di Girolamo, N ;
Chui, J ;
Coroneo, MT ;
Wakefield, D .
PROGRESS IN RETINAL AND EYE RESEARCH, 2004, 23 (02) :195-228
[9]   Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema [J].
Emerson, M. Vaughn ;
Lauer, Andreas K. .
BIODRUGS, 2007, 21 (04) :245-257
[10]  
GANS L, 1996, FOCAL POINTS 0